Beyond Market Intelligence/GLP-1s

GLP-1s

Beyond Market Intelligence keeps GLP-1s in one place: one story so far. The section currently leads with “AI Biotech Enveda Accelerates Drug Development with $311M Investment”. Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every GLP-1s story on Beyond Market Intelligence, newest first.

AI Biotech Enveda Accelerates Drug Development with $311M Investment
TechCrunch

AI Biotech Enveda Accelerates Drug Development with $311M Investment

Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. The $2B valuation reflects real momentum, especially as the company targets skin conditions and tackles the stubborn problem of weight regain after GLP-1s. That's practical science with tangible outcomes. We're watching a biotech that understands the patient's journey, not just the lab bench. For more on who's betting big on emerging tech, check our piece on Wahlberg and Lee's upcoming Disrupt discussion.